WebContact Email [email protected] Phone Number 617-679-1970 FORMA Therapeutics is a biopharmaceutical company integrating transformative biology and chemistry to unlock targets and pathways that have been validated through genomic medicine as root causes or major drivers of human cancers. WebGet Verified Emails for 364 FORMA Therapeutics, Inc. Employees. 5 free lookups per month. No credit card required. The most common FORMA Therapeutics, Inc. email format is [first_initial] [last] (ex. [email protected]), which is being used by 100.0% of FORMA Therapeutics, Inc. work email addresses.
FORMA Therapeutics Announces Frank D. Lee as Chief Executive …
WebForma Therapeutics Holdings Inc is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. The firm's pipeline products are Etavopivat, FT-7051, FT-8225, and others. Contact Information Website WebForma Therapeutics (Nasdaq: FMTX) is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients... heal austin austin tx
FORMA Therapeutics Company Profile Management and …
WebFORMA THERAPEUTICS Overview Website: www.formatherapeutics.com Headquarters: Watertown, MA Size: 51 to 200 Employees Founded: 2008 Type: Company - Public (FMTX) Industry: Biotech & Pharmaceuticals Revenue: $5 to $25 million (USD) Competitors: Unknown We are driven by our purpose: patients. WebFORMA Therapeutics Main Industry Pharmaceuticals, Manufacturing Website www.formatherapeutics.com Contact Information Headquarters 500 Arsenal St, Ste 100, Watertown, Massachusetts, 02472, United States (617) 679-1970 Branford, Connecticut Office 35 NE Industrial Rd, Branford, Connecticut, 06405, United States (203) 483-8490 WebNov 12, 2024 · WATERTOWN, Mass.--(BUSINESS WIRE)-- FORMA Therapeutics, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today reported financial results for the third quarter ended Sept. 30, 2024.The company also highlighted … heal a uti